

**“EVALUATION OF THYROID DYSFUNCTION IN  
DIFFERENT STAGES OF FEMALES”**



**L**OVELY  
**P**ROFESSIONAL  
**U**NIVERSITY

---

*Transforming Education Transforming India*

**FULL TERM TRAINING REPORT SUBMITTED TO  
LOVELY PROFESSIONAL UNIVERSITY, PUNJAB  
IN THE PARTIALFULFILMENT OF REQUIREMENTS**

**FOR THE DEGREE OF  
MASTER OF SCIENCE**

**IN**

**CLINICAL BIOCHEMISTRY**

**SUBMITTED BY**

**SAPNA RANI**

**REG.NO. 11300726**

**LOVELY SCHOOL OF PHYSIOTHERAPY AND PARAMEDICAL SCIENCES  
LOVELY PROFESSIONAL UNIVERSITY, PUNJAB, INDIA**



**L**OVELY  
**P**ROFESSIONAL  
**U**NIVERSITY

---

*Transforming Education Transforming India*

## **CERTIFICATE**

This is to certify that the present full term training report entitled "**Evaluation of thyroid dysfunction in different stages of females** " is the outcome of the original piece of work carried out by Sapna Rani (Registration No: 11300726) herself under my guidance and the contents of her report did not form a basis of the award of any previous degree to her and to the best of my knowledge to anybody also. The report has not been submitted by the candidate for any research degree in any other University. The training report is fit for submission to the partial fulfillment of the conditions for the award of M.Sc. in Clinical Biochemistry. Further certified that the candidate in habit and character is a fit and proper person for the award.

**(Dr. Ekta Chitkara)**

**Internal Supervisor.**



**Govt. Medical College and Hospital Jammu**  
**Department of Biochemistry.**

**Certificate**

Certified that the data included by Sapna Rani in the training report titled “Evaluation of thyroid dysfunction in different stages of females”, is genuine and relates to her work done under our supervision and guidance. To the best of our knowledge and belief, the work presented here, it has not been submitted in part or in full for the award of any degree or academic distinction to any learned body and is in accordance with the approved plan of training report.

**Signature:**

**Dr. A.S. Bhatia**  
**MBBS (MD)**  
**HOD of Biochemistry**  
**(External Guide)**

**Signature:**

**Mrs Kapila Raina**  
**(Lecturer of**  
**Biochemistry**  
**(External Co- Guide)**


# GOVERNMENT MEDICAL COLLEGE JAMMU

## TO WHOM IT MAY CONCERN

This is to certify that Ms. Sapna Rani D/o Sh. Bharat Bhushan student of M.Sc (Clinical Biochemistry) from Lovely Professional University, Phagwara, Jalandhar (Punjab) has completed three months internship training in the department of Biochemistry of this college w.e.f. 23-01-2015 to 25-04-2015.

No: JMC/UG/734

Dated: 5-05-2015

  
Principal & Dean  
Govt. Medical College,  
Govt. Medical College,  
Jammu

# DECLARATION

This is to certify that, the work embodied in this training report was carried out by me in the Department of Biochemistry at Govt. Medical College and Hospital Jammu. Under the direct supervision of **Dr. A.S. Bhatia** HOD of Biochemistry, **Mrs. Kapila Raina** Lecturer of Biochemistry (Govt. Medical College and Hospital Jammu) and **Dr. Ekta Chitkara** Assistant professor at Lovely Professional University

**Sapna Rani.**

**Registration No (11300726)**

## Acknowledgement

It gives me as immense pleasure to express my profound gratitude to all those respectable personalities who helped me to complete my project work

First express my gratitude to Almighty who blessed us and the most beneficent and merciful.

My deepest and sincere gratitude goes to my internal supervisor **Dr. Ekta Chitkara**, Assistant Professor at Lovely professional University, Punjab for the incisive observation, constant encouragement, tremendous support, valuable supervision, patience and guidance on our mistakes and suggestion throughout the tenure of my training project.

I would like to express my deep sense of gratitude my external guide **Dr. A S Bhatia (MBBS)** Head of Department of Biochemistry, **Mrs. Kapila Raina** Lecturer of Biochemistry (Govt. Medical College and Hospital Jammu).

I would like to acknowledge **Mr. Vijay Sharma** (Biochemist), **Mr. Ajay Pradhan**, **Mr. Mukhtyar**, **Mrs. Rajni**, **Mrs. Paramjeet** and all the technical staff of biochemistry laboratory. They all helped me in learning technical work of the laboratory. I would also acknowledge **Mrs. Chandni** for giving me valuable suggestion for representation of this report

I would like thank my honorable Dean Mam **Dr. Monika Gulati**, Senior Dean of Lovely Professional University, **Mr. Gurinder Singh**, (COD) Department of Paramedical Sciences, Lovely Professional University, Punjab for their valuable suggestion and helping attitude.

I am immensely thankful to my family members and friends who have encouraged me and supported me throughout the project.

I would equally thanks to all the patients who showing faith on us and show an overwhelming cooperation to and provide me opportunity to pursue my project work in field of diagnosis. It would be unjustified if I fail to acknowledge to all those persons who directly or indirectly helped me in completing this project work

**Sapna Rani**

## Table of contents

S.NO	Contents	Page no.
	Certificate	I-IV
	Declaration	V
	Acknowledgement	VI
	List of Contents	
1	Abstract	
2	Introduction	1-10
3	Literature review	11-14
4	Aims and objectives	15-16
5	Material and Methods	17-25
6	Results	26-35
7	Discussion	36-38
8	Conclusion	39
9	References	40-54

## **Abstract**

The thyroid gland is considered as the largest gland in the body located below the voice box and secretes two hormones, thyroxine and tri-iodothyronine. These hormones are necessary for performing various functions of the body. In India, 1.21 billion people are believed to suffer from thyroid dysfunction, and their prevalence is higher in females than in males. Thyroid disorder causes various complications for females, such as infertility and subfertility in reproductive females and, in pregnancy, causes abortion as well as intellectual impairment to the fetus. Bone mineral density decreases in menopausal females as a result of deficiency of estrogen hormone and other hormones which are responsible for affecting bone metabolism; this can be due to thyroid hormones in addition to sex steroids.

In this study, 144 females participated. Out of these, 39 (27%) females were affected through subclinical hypothyroidism with a raised level of TSH and normal levels of  $T_3$  and  $T_4$ , and 8 (5.5%) females were affected with subclinical hyperthyroidism with a low TSH level and normal  $T_3$  and  $T_4$ . These all females belonged to three different groups: reproductive, menopausal, and pregnant. Among these 39 females affected through hypothyroidism, 18 reproductive females were affected through hypothyroidism with a raised TSH level, having mean values of  $(7.50 \pm 2.4)$  and 14 pregnant females were affected through hypothyroidism with mean values of  $(8.51 \pm 6.4)$ , and 7 menopausal females had subclinical hypothyroidism with mean values of their TSH level of  $(12.6 \pm 12)$ . In 8 females affected through hyperthyroidism, 5 females belonged to the reproductive group, 2 females belonged to the menopausal group, and only one pregnant female showed a low TSH level. Thus, females are mostly affected through hypothyroidism, and high prevalence is seen in the reproductive age group. Due to thyroid dysfunction, these females showed symptoms of an abnormal menstrual cycle. So, evaluation of thyroid hormones is necessary in females for diagnosis to prevent abnormalities in pregnancy and result in a healthy full-term life birth, and in reproductive females for diagnosis of infertility.



## **Chapter 1**

---

---

# **INTRODUCTION**

---

---



## **Background**

Thyroid gland which is normally located in the front of the neck and vertebrate anatomy it is considered as the largest gland in the body(1,2). The two hormones thyroxine( $T_4$ ) and triiodothyronine( $T_3$ ) collectively called thyroid hormone secreted by this gland which act throughout the body influencing metabolism, growth and development and body temperature(3-5). The most prevalent endocrinopathies across the world is thyroid diseases (6). These are considered as 2<sup>nd</sup> most common glandular disorder of the endocrine system and are increasing predominately among women (7). Thyroid dysfunction is prevalent among women of reproductive age when compared with men. In India about 42 million people are believed to be affected with thyroid disorder(8). According to other estimation in India with a population of 1.21 billion, an estimated 108 million people suffer from endocrine and metabolic disorder (9). For screening and evaluating thyroid dysfunction thyroid function test panel is commonly used. Adequate thyroid hormone ( $T_4$  and  $T_3$ ) crucially required for brain development during infancy and childhood (10-16).

### **Different stages in females with hormonal changes:**

#### **Reproductive stage:**

On the basis of ovarian function females reproductive stage are classified into three main phases- follicular, ovulatory and luteal. These three phases are controlled by pituitary hormonal signals. A female in ovulatory phase goes through an average ovulatory menstrual cycle (MC) that last 28 days but may range from 20-45 days (17). Over the course of an ovulatory menstrual cycle hormonal fluctuations take place which is well defined predictable pattern (18, 19). Various female hormones like Luteinizing hormone (LH) and follicle stimulating hormones and the sex steroids intricate feedback mechanisms. The phases of an ovulatory cycle differentiate by the varying concentration of estradiol and progesterone. Concentration of both hormones low during follicular phase(FP), estrogen is high and progesterone low during the ovulatory phase(OP), and both are high in the luteal phase(17). Hypothyroidism prevalence in the reproductive age(20-40 years) of females and varies from 2% and 4%(20,21). It is a broad spectrum of reproductive disorder ranging from abnormal sexual development through menstrual irregularities to infertility is associated with hypothyroidism. Since 1950s the impact of hypothyroidism on the menstrual cycle has been identified which leads to changes in cycle length and blood flow (22, 23).

**Pregnant stage:** In pregnancy the female hormone estrogen and progesterone helped in releasing egg from ovary and implant in the uterus lining. There is many other hormonal changes take place in pregnancy to maintain the cellular and molecular demand of maternal and physiological requirements (24-26). Like more hormone are produce when body need excess energy in certain situation which include growth, coldness or during pregnancy. In pregnancy and to sustain a healthy pregnancy normal thyroid function is necessary. There are various effect of thyroid hormone have been seen on pregnancy and reproduction (27). In normal pregnancy concentration of estrogen begins to elevate and due to its effect on liver concentration of serum TBG level also increases. As a result of increased TBG concentration the thyroid hormone ( $T_3$  and  $T_4$ ) concentration also begin to increase. As a result of over activity of thyroglobulin during pregnancy which show the hyperactivity of thyroid gland seen during normal, pregnancy with increased  $T_3$  and  $T_4$  concentration.(28,29)

**Menopause stage:**

Menopause is defined as the permanent end of menstrual cycles resulting end of female reproductive life (infertility). This occurs due to the loss of ovarian follicles (30). Females life is classified in three categories according to STRAW (staging of reproductive aging workshop) Reproductive, Menopausal transition and post Menopause. These include menstrual and qualitative hormonal criteria to define each stage. Late reproductive age being characterized by elevated early cycles and when females begin to notice change in the menstrual cycles with marks the time begin to decline. Due to changes in menstrual cyclicity critical endocrine parameter begin to change, and these hormonal changes are important in fertility assessments. This stage is subdivided into two stages. In first stage there are no changes in menstrual cycles or early follicular phase and in 2<sup>nd</sup> stage shorter cycles begins (31-33). This stage is also characterized by variable but elevated early follicular phase and low AMH levels and AFC. Late menopausal transition defines by the occurrence of amenorrhea of 60 days or longer. Increase variability in cycle's length is seen in menstrual cycles in the late menopausal transition. Extreme flocculation in hormonal levels and increased prevalence of anovulations is seen in this stage. Late postmenopausal represents the periods in which further changes in reproductive endocrine functions are more limited and processes of somatic aging become of paramount concern(34-36). FSH level going to decrease after many years of menopause in old females (37, 38). Deficiency of certain hormone such as estrogen, progesterone, testosterone and dehydroepiandrosterone(DHEA)seen(39-44) in menopausal women with increase in

lutinizing hormone (LH), follicle stimulating hormone(FSH) and thyroid stimulating hormone(45-48). These hormone play individual role in the human body include cardiovascular gastrointestinal and immunological function. Emerging evidence from the ongoing research suggest that the association of high TSH levels, with two folds risk of cognitive decline as well as prevalence of abnormalities in mucoskeletal seen in menopausal females(49,50).

### **Thyroid Hormones and its secretions**

Thyroid gland is known to secrete the major catabolic hormones namely thyroxine( $T_4$ ) and tri-iodotyronine ( $T_3$ ). Although  $T_3$  is produced from thyroid secretion but 80%of  $T_3$  is produced by de-iodination of  $T_4$  (51) most biologically active among thyroid hormones is  $T_3$  and inter conversion of  $T_4$  into  $T_3$  is accomplished by the action of enzyme 5 deiodonase in the peripheral tissues of liver and kidney.  $T_4$  consist 4 iodine atoms  $T_4$  is transferred or changed into  $T_3$  by the removal of one iodine atom of  $T_4$  (52). TSH is another hormone which is formed in pituitary gland is responsible for controlling  $T_4$  secretion by the thyroid gland. Therefore the primary responsibility or the primary role of TSH is to control the synthesis and secretion of thyroid hormones. The secretion of TSH is govern by another hormone TRH (thyrotropin releasing hormone) which is secreted by hypothalamus (master gland) (53). In conclusion synthesis and secretion of thyroid hormone is regulated by negative feedback system that involves the hypothalamus, pituitary and the thyroid gland (fig1).




Figure 1. Showing the secretion of thyroid hormones

## **Structure and physical chemistry of THs (thyroid hormones) with formations**

The structure of thyroid hormone is somewhat similar as examined by different studies suggesting that thyroid tissue comprises of follicular epithelium cells that covers the lumen filled with colloid. Follicles are found to be arranged together into thyroid gland in contrast to this follicles are spread in the anterior region of the body (54). The secretion of thyroglobulin protein into the central lumen of the follicles take place when thyroid epithelial cells take up iodine from the circulation. Per molecule of thyroglobulin contains more than 100 tyrosine residues out of which many tyrosine residues are being iodinated at ortho to the phenolic hydroxyl groups in order to form  $T_4$  reflects the arrangement of thyroglobulin. In some condition of iodine deficiency more  $T_3$  and less  $T_4$  level are synthesized (55). Chemical structure of  $T_3$  and  $T_4$  hormones along with its molecular structure is depicted and the outer phenolic ring builds in a place which is perpendicular to the phenolic ring. Two iodothyronines are called as reverse  $T_3$  ( $Rt_3$ ) and 3, 5 di-iodothyronines both are being synthesized from natural tyrosine residues. Amino acid part of these molecules is L- isomer configuration. The molecular mass of  $T_4$  is 777g/mol and  $T_3$  is 651g/mol. The only molecules in the body that are known to contain iodine are thyroid hormones and their metabolites. Iodine atom has a role in making most of the molecular mass of thyroid hormones. These iodine atoms are the heaviest elements in the body. Selenium is the next heaviest element in the body with atomic mass of 79 and is considered as important part of enzyme which role is to de-iodize the thyroid hormones. These iodine atoms have powerful electron binding energies and are electron attractive. The carboxyl groups along with amino and phenolic groups are basically ionizable parts of these molecules. About 50% of dissociation of simple phenolic groups occurs at pH of 10. The pH of phenolic group of  $T_3$  can be reduced to 8.45 by the presence of a single iodine atom that must be electron attractant to the outer  $T_3$  ring. The presence of two iodine atom on outer  $T_4$  ring further decrease the pH of its phenolic groups to 6.73(56). Both the  $T_3$  and  $T_4$  have relatively have low solubility at acidic pH but increased solubility at acidic pH in a dramatic way. Further  $T_3$  is more hydrophobic than  $T_4$  because of the lack of its ionized phenolic group. Thus this becomes the base for common practice of using alkaline solution while injecting thyroid hormones. As the hormones are soluble in the injectable so, once they go inside our body-they are found back to make natural environment or even acid one and finally will be more hydrophilic in nature (57).

### **Importance of thyroid hormones:**

The thyroid hormones have a role in maintenance BMR-basal metabolic rate and homodynamic state of most of the body cells (58). They are responsible for maintaining the normal growth development and functions of almost all the cells of the body with major effect on metabolic rate and oxygen consumption (59). BMR of hepatocytes(liver cells) are also regulated by these hormones thus maintaining the normal functioning of liver. The thyroid hormones and their metabolites regulate endocrine effect in a systemic manner (60). For both normal hepatic circulation and normal bilirubin metabolism normal circulation of thyroid hormones are required.(61) These have wide variety of effects on nervous system and thyroid dysfunction correlate with peripheral neuropathy, cognitive impairment and other disorder of the body like anxiety and depression(62). They also have an effect on the muscular system(63) Cardiovascular system bone formation (eretheropiosis) and on oxidation stress(64) implication of these thyroid disfunction can lead to high risk of morbidity and have adverse effect on health.(65,66) Thyroid hormones are closely involved in cellular metabolism and idothyrosine effect the metabolism of carbohydrates, proteins and lipids are recorded(67).

### **Disorder of thyroid hormones:**

The most common endocrine disorder in our country is thyroid dysfunction (68). Due to primary failure of thyroid gland thyroid dysfunction occurs (69). The variety of thyroid dysfunction ranges from a condition of hypothyroidism (under active) to hyperthyroidism (over active). The clinical and biochemical classification of thyroid hormone include

- Due to thyroid gland dysfunction itself i.e. primary disorder (primary hyperthyroidism and primary hypothyroidism)
- Due to pituitary gland disorder called secondary disorder (secondary hypothyroidism and hyperthyroidism)
- As a result of hypothalamic diseases known as tertiary disorder (tertiary hyper and hypothyroidism)(70).

As a response to several thyroid disorders either excess or deficiency of thyroid hormones occurs. Both thyrotoxicosis and hypothyroidism intensely impact the cardiovascular system, digestive system, metabolism, neuro-psychological functions, muscles and cutis (71).

## **Hyperthyroidism:-**

Hyperthyroidism or thyrotoxicosis is result due to the effect of excess thyroid hormone, there are different disorder triggered by it. In thyrotoxicosis the level of TSH low or undetectable level in serum and free hormone level remain normal (72). Overt thyrotoxicosis another condition of hyperthyroidism which is defined by suppressed serum thyrotropin (TSH) and elevated free thyroid hormone concentration (73). There are multiple symptoms of hyperthyroidism present that varying according to the age of patient, magnitude of hormone excess, and presence of comorbid condition. On the basis of common sign and symptoms clinical presentation of between older and younger patients done. The diagnosis of older people becomes difficult due to presence of paucity of classic sign and symptoms (74). After a stress full illness in patients of thyroid storm (a rare presentation of hyperthyroidism) with untreated or under treatment patient of hyperthyroidism symptoms like delirium, severe tachycardia, fever, vomiting, diarrhea and dehydration seen (75).

### **Causes of hyperthyroidism**

The most common causes include Graves disease (GD), toxic multinodular goiter (TMNG), and toxic adenoma.

**Graves disease:** The common cause of hyperthyroidism is Graves disease which accounts for 60 to 80 percent in all cases. This is caused by an antibody which is active against the receptor of thyroid stimulating hormone (TSH), thus stimulating the gland to synthesize and secrete excess thyroid hormone (T3 and T4). It is a type of autoimmune disease (76).

**Toxic multinodular goiter:** Approximately 5% of the cases of hyperthyroidism are caused by toxic multinodular goiter and it is commonly found in iodine deficient areas. It is mostly seen in older patients of above 40 years of age and its onset is more dangerous than Graves disease (77).

**Toxic adenoma:** toxic adenomas are a type of nodules that function separately. It is common in both the younger patients and in iodine deficient areas (77).

### **Hypothyroidism:**

Hypothyroidism is categorized by low T3 and T4 and high TSH level it is common endocrine disorder due to deficiency of thyroid hormones. The most common cause of hypothyroidism is autoimmune thyroid disease (Hashimoto disease) in areas of adequate iodine intake (78).



Hypothyroidism is more common in females having low body mass index during childhood and small body size at the time of birth (79). Due to deficiency of thyroid hormones wide range of effect occurs. This includes either derangement in metabolic process or direct effect by accumulation of glycosaminoglycans in the tissues. As a result of hypothyroidism delayed puberty, anovulation, menstrual irregularities and infertility are common. So, TSH screening should be a routine part of any investigation into menstrual irregularities or infertility.

### **STATUS OF THYROID HORMONES IN DIFFERENT STAGES OF FEMALES :**

**In reproductive age group:** Thyroid disease if remain undiagnosed and untreated it can cause infertility as well as sub fertility in females of reproductive stage. In our society these conditions have important medical, economical and psychological implications. Females fertility rate are affected by abnormality of thyroid function is accomplished through various ways resulting in imbalance in sex hormones, luteal phase defect, in anovulatory cycles and high prolactin (PRL) levels. Therefore in fertility, pregnancy and to sustain a healthy pregnancy normal thyroid function is necessary, even in the earliest days after conception. In any females who want to get pregnant thyroid evaluation is done with family history of thyroid dysfunction or irregular menstrual cycle or had more than two miscarriages or unable to conceive after 1 year of unprotected intercourse (80-82). In the reproductive age group prevalence of hypothyroidism is 2-4% and considers a cause of infertility and habitual abortion(83,84). By assessing TSH level in blood hypothyroidism can be easily detected. Subclinical hypothyroidism associated with a slight increase in TSH level with normal T3 and T4 level and low T3 and T4 with high TSH level indicate clinical hypothyroidism. (85)Subclinical hypothyroidism directly cause anovulation or by causing elevation in PRL. Due to increased production of thyrotropin releasing hormone (TRH) many infertile women had associated hyperprolactinemia in case of hypothyroidism (86,87). The common cause of infertility is thyroid dysfunction in reproductive females which can be easily managed by correcting the appropriate level of thyroid hormones(88,89). If both hypothyroidism and hyperprolactinemia is present firstly need to correct hypothyroidism before evaluating further cause of hyperprolactinemia. Thyroxine is the choice of hormone therapy in treatment of hypothyroidism. Menstrual cycle is normalizing by it. It also improves the fertility rate. Therefore for fertilization, the normal TSH level is the pre-requisite requirement. Autoimmune thyroid disease is most common cause of hypothyroidism in this age group(90,91). Due to numerous interactions of thyroid hormone with the female reproductive system severe hypothyroidism is commonly associated with ovulatory dysfunction. As a

result of altered GnRH pulsatile secretion delay response in LH seen and inadequate corpus luteum have been reported (92-94). By the presence of thyroid receptor on human oocytes thyroid responsiveness by the ovaries could be explained (95). To exert direct stimulating effect on granulosa cell function (progesterone production) thyroid hormone also synergizes with the FSH mediated LH/hCG receptor (96). According to the study of Cramer et al., showed that serum TSH level became a significant predictor of failure of IVF, and it has been reported that in females who produced oocytes that failed to be fertilized TSH levels were significantly higher (97). The impact of hypothyroidism on fertility followed by two pathways i.e. by altering the peripheral metabolism of estrogen and by decreasing SHBG production. As a result of both of these pathways abnormal feedback of the pituitary level is seen. By decreasing the production of coagulation factors (factor VII, VIII, IX and XI) hypothyroidism is also responsible for causing menorrhagia independently of hormonal changes (98). In hyperthyroid women SHBG production increases, as a result of hyperthyroxinemia increases the gonadotropin response to GnRH it also has an effect on haemostatic factors in relation to decrease in menstrual flow (99,100). Even though these metabolic changes, hyperthyroid women usually maintain regular cycles (101). These cycle changes can frequently be corrected by the treatment of hyperthyroidism. The exact effect of hyperthyroidism on fertility remains ill defined (102). AITD (autoimmune thyroid disease) is seen 5-10 times higher in women than in men, this is explained by genetic factors, the effect of oestrogen and perhaps chromosome X abnormalities (103-106). For normal reproductive function synthesis of steroid hormones by oocytes is dependent on adequate levels of thyroid hormones. FSH and LH action on steroid biosynthesis is modulated by T<sub>4</sub> and T<sub>3</sub> binding sites which have been identified in human and mouse oocytes (98,99). The action of estrogen is enhanced by thyroid hormones. Whereas the impact of T<sub>3</sub> on female reproduction or alteration in T<sub>3</sub> level in case of AITD has a physiological relevance in fertility further investigation is required (107,108).

### **IN PREGNANCY:**

Thyroid dysfunction is not only seen in reproductive age its prevalence is also seen in pregnancy. The prevalence of thyroid dysfunction in pregnancy is 2-3% and the main cause is autoimmune thyroiditis. During the first trimester of pregnancy both thyroid dysfunction and thyroid autoimmunity have independently been associated with adverse pregnancy outcomes (109). All circumstances should be optimal in early pregnancy, in order to achieve an optimal pregnancy outcome, namely a healthy full term live birth. During the first trimester adequate functioning of the maternal thyroid is required, because development of the fetus brain starts at this

stage and fetus not able to produce its own thyroid hormone (110). Hypothyroidism particularly caused due to the deficiency of iodine in pregnancy stage. Due to the deficiency of iodine it causes thyroid deficiency in both in mother as well as in fetus(111).It creates a situation which make difficult to determine whether the mental retardation due to maternal hypothyroidism or both maternal and fetus hypothyroidism(112). The cause of hypothyroidism is chronic autoimmune thyroiditis among women in child bearing age in developed countries. Antibodies which are responsible to altering thyroid dysfunction of maternal can cross the placenta and in some instance, compromise fetal and neonatal thyroid function (113-118). Thyrotropin–receptor blocking antibody that identified by screening programs for newborn. It has been implicated in cases of transient congenital hypothyroidism (119). For the development of fetus central nervous system, the importance of maternal thyroid hormones is well established. Fetal thyroid gland cannot synthesize iodothyronine until after 10weeks of gestation at this stage therefore maternal thyroxine particularly needed. So, for normal neuro development of fetus maternal as well as fetal thyroid hormone is necessary (120). Due to severe deficiency of iodine result maternal and fetal thyroid insufficiency, thus infant has profound neurologic impairment and mental retardation(121,122). In the first trimester of pregnancy overt hypothyroidism caused by glandular failure load which is also associated with intellectuall impairment during childhood as well as pregnancy complication, it include preeclampsia, plancental abruption, preterm birth, low birth weight and fetal death(123,124). The effect of thyroid deficiency on mild maternal with a normally functioning fetal thyroid gland less clear. It is important in case of thyroid deficiency subclinical hypothyroidism caused, which is associated with elevated serum thyrotropin(thyroid–stimulating hormone) and serum free thyroxine level remain normal.(125,126) In pregnancy the prevalence of subclinical hypothyroidism seen 2 to 5% (127-129). The presence of AITD could be associated with a slight deficiency in thyroid hormones, with increase estrogen level due to inadequate response of the thyroid to adopt the changes, associated with ovarian hyper stimulation. Women had miscarriage significantly lower thyroid hormone level seen in comparison to those who delivered successfully (130). During first trimester of pregnancy thyroid binding globulin (TBG) increases in the beginning, and its value approximately reached double baseline value in the third trimester(131-133). As a result of this during third trimester a marginal fall in free T<sub>3</sub>(FT<sub>3</sub>) and free T<sub>4</sub>(FT<sub>4</sub>) seen in iodine sufficient regions, thus thyroid stimulating hormone start slighting rising. Therefore in third trimester increase level of TSH due to decrease FT<sub>3</sub> and FT<sub>4</sub> with increase in total T<sub>3</sub> (TT<sub>3</sub>) and T<sub>4</sub> (TT<sub>4</sub>) hormone(134-136). During pregnancy

various physiological changes take place which produce alteration in thyroid hormones but also responsible in significant alteration in metabolic process. Due to physiological demand, particularly physical mental and brain development in the first trimester of pregnancy, it should be under specific and particular medical care. To prevent any abnormalities in case of pregnancy thyroid function test is necessary (137-139).

#### **IN MENOPAUSAL FEMALES:**

In menopausal female deficiency of certain hormones seen. This include estrogen progesterone, testosterone and dehydroandrosterone. As a result of estrogen deficiency it causes memory deficits in menopausal females (140). There are certain hormone secretion increase in this stage of female like luteinizing hormone (LH), follicle stimulating hormone and thyroid stimulating hormone.(141-144). These hormones perform various function of the human body including pulmonary, cardiovascular, gastrointestinal and immunological(145,146). Bone mineral density decrease in menopausal females as a result of deficiency of estrogen hormone and other hormone which are responsible to affect bone metabolism are thyroid hormones in addition to sex steroids(147-149). Patients having history with hyperthyroidism in past or present specially taken as a risk factor for osteoporosis, which mainly affect menopausal females. In case of hypothyroidism, the effect on bone reported that bone turnover decreased in adult. In Clinical hypothyroidism due to decrease of thyroid hormone the thickness of cortical bone increase. Whereas no difference in trabecular bone between control and hypothyroid patient(150,151). In hypothyroidism patient bone fracture risk has been reported to increase both before and after diagnosis (152). Hypothyroidism define with abnormal serum thyrotropin concentration in an asymptomatic patient with serum thyroxine(FT4) concentration is normal, it affect more than 10% females older than 60 years(153,154). TSH is consider as negative regulator of skeletal remodeling by reducing the both differentiation of oestoblasts and formation of osteoclasts(155). Therefore mild elevation in TSH level may adversely influence bone in hypothyroid patients. Sex steroid hormones suggesting playing a role in thyroid carcinogenesis. From the support of experimental evidence estradiol help in promoting the proliferation and invasiveness of thyroid cells in vitro(156,157). Reproductive factor such as age at menopause and use of oral contraceptives as exogenous sex hormone have not consistently associated with thyroid cancer.

## Chapter 2

---

---

# **Review Literature**

---

---

In year 2000 Nils Knudsen and colleagues did a comparative study of thyroid functions and types of thyroid dysfunctions on the basis of iodine status in a randomly population of 4694 from the civil registration system in between age group 18 to 65 years. Above age 40yrs patients had hyperthyroidism Ultrasound showed hyperthyroidism associated with macro nodular thyroid structure. Major differences in thyroid dysfunction were found between regions having less difference in iodine excretion. These findings suggested a higher thyroid dysfunctions among elderly persons in the regions where people were iodine deficient (158).

In 2011 Dilutpal Sharma, Akash Gupta *et al.*, 2675 patients participated in this study and they had a history of thyroid disorder together with abnormal thyroid profile (T<sub>3</sub>, T<sub>4</sub> and TSH) and they had undergone thyroid function tests b/w Dec 2012 to Dec 2013. in conclusion patients having normal T<sub>3</sub>, T<sub>4</sub> and TSH were Euthyroid, those having low T<sub>3</sub> T<sub>4</sub> and high TSH hypothyroid and those having normal T<sub>3</sub>, T<sub>4</sub> but low TSH were hyperthyroid particular females were found more susceptible to thyroid hormone disorder. Increased prevalence of hypothyroidism was among age gap of 26-35 years (32%) hyperthyroidism was found in age group of 36-45(7.9%). Hence this study demonstrated that hypothyroidism more prevalent in females(159).

In 2011, Ines Donangelo, *et al.*, gave a comprehensive review on subclinical hyperthyroidism is defined as less or undetectable serum TSH levels with normal FT<sub>4</sub> and total or FTT<sub>3</sub> levels. At the present time third generation assay are capable to detect TSH at levels as low as 0.01 to 0.02 mIU/L Even through suppressed TSH is cost but routinely diagnosis and treatment of low but detectable TSH levels is controversial(160).

In year 2011, Isabela M. Bensenore *et al.*, did a cross section study on 1,373 participants(60.8% women) in order to estimate thyroid disorder among older people. A was done in order to evaluate tri iodothyronine hormone and free-thyroxin hormonal levels. Prevalence of overt hypothyroidism among women was 0.8%, for men 0.4%, subclinical hyperthyroidism in men was 5.4% and in women it was found 2.8%. Further subclinical finding Hypothyroidism in men was found up to 6.1% and in women 6.7%. Since very little or no difference was found in prevalence rates according to gender but nearly 40% of women were already diagnosed and 9% of them under treatment (161).

In the year 2011 Emmy Vanden Boogaard *et al.*, gave a systemic review on significance of subclinical thyroid dysfunction and thyroid autoimmunity before conception and in early pregnancy. They observed prevalence of thyroid dysfunction were common in reproductive

age. This associated with adverse pregnancy outcomes. They conclude pregnant female mostly affected through subclinical hypothyroidism or thyroid antibodies were on a risk of complication like pre-eclampsia, perinatal mortality miscarriage (162).

In 2012, Mirella P. Hage and Sami T. Azaroberserveda relationship between thyroid dysfunction and depression. In this study, it has been explained that thyroid disturbance may significantly affect the mental health status particular depression that may be accompanied by several thyroid abnormalities. Both abnormal and insufficient thyroid hormone can lead to mood swings including depression that is associated with thyroid disorders. Patients have hypothyroidism commonly have feature of depression; while as hyperthyroidism represents a broad spectrum of depression like neuropsychiatric. Symptoms including patients having normal thyroid function do have primarily depression. Hence the underlying mechanisms behind this controversy still remain unclear but needs a further study. However recent advances in genetic, biochemical and neuro imaging fields have provided new approaches thyroid depression relationship (163).

In 2012, Alhamd Alaa Kamal &colleagees examined a clinical evaluation of T<sub>3</sub>, T<sub>4</sub>&TSH in first, 2<sup>nd</sup>&third trimester of pregnancy in the evaluation of hyperthyroidism & hypothyroidism must be assesses by determining serum T<sub>3</sub>, T<sub>4</sub> and TSH levels. In the period of pregnancy various alterations were found in T<sub>3</sub>, T<sub>4</sub> and TSH levels. Thyroid hormones levels were estimated, 35 full term pregnant women taken for study in order to analyze thyroid hormonal imbalance and another 30 groups taken as control. In first trimester of pregnancy serum TT<sub>3</sub> and TT<sub>4</sub> levels were higher than control in 2<sup>nd</sup> stage of pregnancy TT<sub>3</sub> and TT<sub>4</sub> continuously increasing then controls but TSH were significantly lower. In the third trimester TT<sub>3</sub> significantly increased while TSH decreased (164).

In 2013 M.A Samad M.M Haque *et.al.*, In a study of normal participants TSH, T<sub>4</sub>, and T<sub>3</sub> in human serum was done in order to define their normal values were estimated. 201 assays were performed on normal individuals -comprising 26men and 44women with age group - from 2 to 84 years. The normal TSH observed were between 0.5 to 5.0mIU/L. T<sub>4</sub> - 55 - 169nmol/l and T<sub>3</sub> -1.2 -3.4nmol/L(165).

In2013, Dr. SudhaJa and Dr. Naved Ahmad conducted a study on 506 patients to find out prevalence of thyroid dysfunction in different age and sex groups of patients the study revealed that prevalence of Hypothyroidism was higher in the study population & was more prevalent in females & followed by detection & early treatment which helps to avoid

complications, as the diagnosis & management of thyroid dysfunction were still suboptimal (166).

In 2014, Priyatarshini M *et.al* did a retrospective study to find out thyroid disorders among women of reproductive age group. Screening of 1192 patients was done, out of which 63.8% were euthyroid, 27.5% were had gentle or linicut TSH. Between the hyperthyroid and 20.8 were subclinical hyperthyroid. This study discovered hypothyroidism- especially subclinical one was associated with increasing the age and this prevalence of hypothyroidism was on the elevated side among the women's having infertility, PCOS and menstrual disorder(167).



## CHAPTER 3

---

---

# Aim & objective

---

---

## **OBJECTIVES**

- To study the level of various thyroid hormones in females( including pregnant, reproductive and menopausal age group)
- For evaluation of the thyroid hormones, if remain undiagnosed and untreated can cause infertility and sub fertility and normal thyroid function is necessary in pregnancy, fertility and to sustain a healthy pregnancy.
- To compare and correlate the status of thyroid dysfunction including hypothyroidism and hyperthyroidism between the different stages of females.

## CHAPTER 4

---

---

# Material and methods

---

---

## **Material and method**

This study was carried out in the department of biochemistry, Shri Maharaja Gulab Singh Hospital Jammu (SMGS) between 23<sup>rd</sup> Jan 2015 to 24<sup>th</sup> April 2015. A total of 144 females' participated in the study including pregnant, menopausal and reproductive age group. In the first group of 57 females of reproductive stage participated, in 2<sup>nd</sup> group 25 females who were menopausal took part and in third group 64 pregnant females enrolled for the study. Both inpatients and outpatients referred from different unit of Hospital for thyroid profile in the central clinical biochemistry enrolled in the study. The age group, clinical diagnosis and thyroid function profile were estimated which include T3, T4 and thyroid stimulating hormone for all the patients.

Evaluation of total T<sub>3</sub>, T<sub>4</sub> and TSH done by using Architect system. The ARCHITECT totalT<sub>3</sub>(TT<sub>3</sub>), total T<sub>4</sub>(TT<sub>4</sub>) and TSH assay is a Chemiluminescent Microparticle Immunoassay (CMIA) for the quantitative determination of human thyroid hormones (thyroxine and tri-iodothyronine) and thyroid stimulating hormone in human serum and plasma.

### **Selection of patients:**

Following patients were selected for the study.

- Pregnant females for routine checkup to evaluate normal functioning of thyroid hormones.
- Females having history of menstrual irregularities, abortion, heavy bleeding and two cycles in one month
- Females having symptoms like itching on whole body, lower abdomen pain, weakness, sensation of heat in palm and sole region and swelling.
- Females having previous history of thyroid dysfunction

## Requirements

Requirement for collection of sample and for performing test using ARCHITECT assay system procedure.

S.No	Materials
1	Syringes of 2ml
2	Tourniquet
3	Test tubes
4	Test tube stand
5	Centrifuge machine
6	Incubator
7	Refrigerator
8	Auto analyzer( ARCHITECT system)
9	Cups and cup carrier
10	Reaction vials
11	Pipettes (for separating serum)

### Specimen collection and preparation for analysis.

Blood serum was used (including serum collected in serum separator tubes)

#### Step- 1 Collection of sample:

Blood was collected through vein puncture. The three main veins were selected for collection of blood was cephalic, median cubital and median basilica veins. Firstly tourniquet was applied on to the upper arm and disinfectant was applied at the site by using spirit gauge and allows it to dry. 21 gauge needle of 2ml volume was used after collection of blood the tourniquet was released and a wad of cotton wool was placed at the puncture site. The blood was dispensed in the sample tubes.

## **Step- 2 Separation of serums:**

Blood was placed in the incubator for 5-10 minutes for the formation of clot and then centrifuged at 3000rpm for 15 minutes at room temperature. The supernatant serum was assayed for quantitative determination of T<sub>3</sub>, T<sub>4</sub> and TSH.

- While handling patient specimen to prevent cross contamination. Use of disposable pipettes or pipette tip was necessary.

## **Methodology**

**Name:** ARCHITECT Total T<sub>3</sub>, Total T<sub>4</sub> and TSH (Thyroid stimulating hormone)

The ARCHITECT Total T<sub>3</sub> (TT<sub>3</sub>), Total T<sub>4</sub> (TT<sub>4</sub>) and TSH (Thyroid stimulating hormone) assay is a Chemiluminescent Microparticle Immunoassay (CMIA) for the quantitative determination of T<sub>3</sub>, T<sub>4</sub> and TSH.

**For estimation of total T<sub>3</sub>, Total T<sub>4</sub> and TSH.**

### **Principles:**

The ARCHITECT Total T<sub>3</sub>, Total T<sub>4</sub> and TSH assay is a two step immunoassay to determine the presence of Total T<sub>3</sub>, Total T<sub>4</sub> and TSH in human serum using CMIA technology with flexible assay protocols.

In the first step, sample and anti T<sub>3</sub> coated paramagnetic microparticles are combined. T<sub>3</sub> present in the sample binds to the anti- T<sub>3</sub> coated microparticles. For total T<sub>4</sub> estimation, sample and anti-T<sub>4</sub> coated paramagnetic microparticles are combined. Bound T<sub>4</sub> is removed from the binding sites on thyroxine binding globulin, prealbumin and albumin. T<sub>4</sub> present in the sample binds to the anti- T<sub>4</sub> coated microparticles. For TSH sample, anti-β TSH antibody coated paramagnetic microparticles and TSH Assay Diluent are combined. TSH present in the sample binds to anti- TSH antibody coated microparticles.

In the second step T<sub>3</sub> acridinium labeled conjugate is added after washing in case of T<sub>3</sub> and T<sub>4</sub> determination and anti-α TSH acridinium labeled conjugate is added in case of TSH determination. Pre-trigger and trigger solution are then added to the reaction mixture; the

resulting chemiluminescent reaction is measured as relative light unit (RLU). An inverse relationship exists between the amount of total T<sub>3</sub>, total T<sub>4</sub> and TSH in the sample and the RLUs detected by the ARCHITECT *i* optical system.

Figure 2: ARCHITECT *i* optical system



## REAGENTS:

### 1. Microparticles(6.6ml/27.0ml):

For T<sub>3</sub> anti- T<sub>3</sub> (sheep) coated microparticles in MES buffer with IgG stabilizers.  
Minimum concentration: 0.08% solids

For T<sub>4</sub> anti-T<sub>4</sub>(sheep) coated microparticles in TRIS buffer with sheep IgG stabilizers.  
Minimum concentration 0.10% solids.

### 2. Conjugate (5.9ml/26.3ml):

T<sub>3</sub>acridinium–labeled conjugate in citrate buffer with NaCl and Triton X-100 stabilizers. Minimum concentration for T<sub>3</sub> is 0.33ng/ml and for T<sub>4</sub> 0.2ng/ml.

**Fig 3. Reagent kits of TSH**



**Fig4. Reagent kit of T<sub>3</sub>**



**Figure 5. Reagents kit of T<sub>4</sub>**





## Other Reagents

- **Pre-Trigger Solution-** Pre trigger solution containing 1.32%(w/v) hydrogen peroxide.
- **Trigger Solution-** Trigger solution containing 0.35 N sodium hydroxide.
- **Wash buffer.** Wash buffer containing phosphate buffered saline solution.
- **Assay diluents(8.0/40.7ml):** TSH assay Diluent in TRIS buffer

Figure 6 showing the Trigger and Pri-trigger solution.



## ASSAY PROCEDURE

- Before loading the ARCHITECT Reagent kit on the system for the first time, the microparticles bottle required mixing to resuspend microparticles that have settled during shipment.
- the microparticles bottle were inverted 30 times.
- Visual inspection was done until the microparticles were suspended. If microparticles were still adhered to the bottle, bottles were continuously inverted until microparticles had completely resuspended.
- Once the microparticles had been resuspended, remove and discard the cap. Wearing clean gloves, septum was removed from the bag. The septum was carefully snapped onto the top of the bottle.
- Load the ARCHITECT reagent kit on the ARCHITECT *i* System. All the necessary reagent would be present. Ensured that septa should be present on all reagent bottles.
- The minimum sample cup volume was calculated by the system and was printed on the Orderlist report. No more than 10 replicates may be sampled from the same sample cup.
- If using primary or aliquot tubes, sample gauge was used to ensure sufficient patient specimen.
- ARCHITECT Total T<sub>3</sub>, T<sub>4</sub> and TSH calibrator were mixed by gentle inversion prior to use.
- To obtain the recommended volume requirements for the ARCHITECT assay, the bottles were vertically held and dispense 4 drops of each calibrator into each respective sample cup.
- Sample was loaded

Press RUN. The ARCHITECT *i* system performs the following function:

- Moves the sample to the aspiration point
- Loads reaction vessels (RV) into the process path.
- Aspirates the transfer sample into the RV
- Advances the RV one position and transfers microparticles into the reaction mixture.
- Adds pre-trigger and trigger solution.

- Measures chemiluminescent emission to determine the quantity of total T<sub>3</sub> and T<sub>4</sub> and TSH in the sample.

**Limitations of the procedure:**

- Specimen run on the ARCHITIECT assay must be processed according to the specimen test tube manufacture’s instruction. Insufficient processing including deviations from recommended clotting times, centrifugation times, centrifugation speed and sample preparation techniques may cause inaccurate results.
- For diagnostic purpose result should be used in conjunction with other data; e.g., symptoms clinical impressions, etc.
- If the T<sub>3</sub>, T<sub>4</sub> and TSH are inconsistent with clinical evidence, additional testing is suggested to confirm the test.
- Some patients specimen show increased or decreased falsely result because these patients received mouse monoclonal antibodies for diagnosis or therapy may contain anti-mouse antibodies (HAMA). Additional information required for diagnosis this kind of patients (168, 169). Additional information may be required for diagnosis.
- Heterophilic antibodies in human serum can react with reagent immunoglobulins, interfering with in vitro immune assay (170) Patients routinely exposed to animal or animal serum products can be prone to this interference and anomalous values may be observed. Additional information may be required for diagnosis.

**Expected Values**

**Normal Range of TSH**     0.35-4.9Uiu/ml

**T<sub>3</sub> (total T<sub>3</sub>)**            0.58-1.59ng/ml

**T<sub>4</sub> (total T<sub>4</sub>)**            4.87-11.72ug/dl

## CHAPTER 5

---

---

# Results

---

---

## Results

A total no of 144 females participated in the study those females were for evaluation of thyroid profile in the laboratory of biochemistry of Shri Maharaja Gulab Singh Hospital Jammu. Evaluation of thyroid was profile done in three groups, group one of reproductive age group, group pregnant females and third group was comprised of menopausal females. A total of 57 females belong to first group of reproductive age group, group 2<sup>nd</sup> having comprised of 25 females that had gone through menopausal age and in group 3<sup>rd</sup> total 62 pregnant females participated.

Table No.1 Different groups of females


Different Stages	Total No of females (n=144)
Reproductive age group	57
Pregnant	62
Menopausal	25

In the first group 18 females showing raised level of TSH with normal level of T<sub>3</sub> and T<sub>4</sub>. The mean value of TSH was 7.50±2.4, T<sub>3</sub> (1.235±0.31) and T<sub>4</sub> (7.55±2.1). The female having normal T<sub>3</sub>, T<sub>4</sub> and TSH level in this group were 34. The mean values of their T<sub>3</sub> (1.39±0.514), T<sub>4</sub> (6.88±2.628) and TSH (2.4±1.06). Out of these 57 only 5 females found with low TSH level with normal T<sub>3</sub> and T<sub>4</sub>. The mean values of their TSH was (0.162±0.038), T<sub>3</sub>(1.515±0.3), and T<sub>4</sub>(12.76±1.04). Thus on the basis of TSH level distribution of subclinical hypothyroid having high TSH level were found in 31% females, subclinical hyperthyroidism having low TSH level were in 9 % females and rest 60% were comes under euthyroid having normal T<sub>3</sub>,T<sub>4</sub> and TSH level. Table 1 showing the result of T<sub>3</sub>, T<sub>4</sub> and TSH in reproductive age group. (Refer table 1)

**Table 1 Result obtained in the present study of Reproductive Age Group**

Total no. of patients (n=57)	Age	TotalT <sub>3</sub> (ng/ml)	Total T <sub>4</sub> (ug/dl)	TSH (Uiu/ml)
	Mean±SD	Mean±SD	Mean±SD	Mean±SD
Hypothyroid (n=18)	28±6.29	1.23±0.30	7.55±2.1	7.5±2.4
Hyperthyroid (n=5)	24±4.9	1.515±0.30	12.7±1.04	0.16±0.038
Euthyroid (n=34)	25±4.6	1.3±0.51	6.8±2.68	2.4±1.0

**Figure 7: Distribution of thyroid dysfunction in reproductive age group**




In the 2<sup>nd</sup> group of menopausal female 25 females participated. Out of this 7 females found with raised level of TSH with normal T<sub>3</sub> and T<sub>4</sub> level. The mean values of age (59.14±7.1) The mean values of total T<sub>3</sub> 1.16±0.04, T<sub>4</sub> was 7.97±2.16 and TSH 12.6±12. Only two females showing the low TSH level with normal T<sub>3</sub> and T<sub>4</sub> level. Rest of 16 having normal level of all the parameters. Thus distribution of thyroid dysfunction in this group showing in Table 2

**Table 2: showing the result of T<sub>3</sub>, T<sub>4</sub> and TSH in menopausal females**

<b>Total no. of patients (n=25)</b>	<b>Age</b>	<b>Total T<sub>3</sub>(ng/ml)</b>	<b>Total T<sub>4</sub>(ug/dl)</b>	<b>TSH (Uiu/ml)</b>
	Mean±SD	Mean±SD	Mean±SD	Mean±SD
<b>Hypothyroid (n=7)</b>	59.14±7.14	1.16±0.04	7.97±2.16	12.6±12
<b>Hyperthyroid (n=2)</b>	54±6.6	1.15±0.07	8.14±1.	0.18±0.02
<b>Euthyroid (n=16)</b>	57±9	1.2±0.53	6.9±2.67	2.155±1.0



**Figure 8: Represents the menopausal females affected with thyroid dysfunction**




In 3<sup>rd</sup> total number of pregnant females was 62 that took part in the study. Among all these 14 females having previous history of thyroid dysfunction affected through raised level of TSH with normal T<sub>3</sub> and T<sub>4</sub> level and rest 47 was having normal level of T<sub>3</sub>, T<sub>4</sub> and TSH. Only one female belonging to this group showed the low level of TSH (Refer table 3)


**Table No 3 showing the result of pregnant female**

Total no. of patients (n=62)	Age	Total T <sub>3</sub> (ng/ml)	Total T <sub>4</sub> (ug/dl)	TSH(Uiu/dl)
	Mean±SD	Mean±SD	Mean±SD	Mean±SD
Hypothyroid (n=14)	26.1±3.4	1.4±0.34	5.9±2.1	8.5±6.40
Hyperthyroid (n=1)	27	1.6	8.0	0.07
Euthyroid (n=47)	24±3.9	1.4±0.47	7.0±2.0	2.1±1.2

**Figure 9: Represents the distribution of thyroid dysfunction in pregnant females**



**Figure10: represents the level of T<sub>3</sub>, T<sub>4</sub> and TSH in hypothyroid females of all the three groups**




**Normal Range of TSH** 0.35-4.9Uiu/ml

**T<sub>3</sub> (total T<sub>3</sub>)** 0.58-1.59ng/ml

**T<sub>4</sub> (total T<sub>4</sub>)** 4.87-11.72ug/dl

**Figure 11: Distribution of thyroid disorders in different females**



## CHAPTER 6

---

---

# Discussion

---

---

## Discussion

In the present study, we evaluate the level of T<sub>3</sub>, T<sub>4</sub> and TSH in the females of different stages of life as reproductive, pregnant and menopausal. Prevalence rate of thyroid disorder were found to increase among females in the study of Dr. SudhaJha *et al.* 2013. In our study the females of reproductive age group were mostly affected through subclinical hypothyroidism and their prevalence was higher than that of pregnant and menopausal females. Most of these females had previous history of menstrual irregularities, lower abdomen pain and some of them have undergone through abortion. The prevalence of hyperthyroidism in this group was also high in contrast to pregnancy and menopausal. In case of hypothyroidism the level of TSH raised due to increase production of TRH (thyroid stimulating hormone) and stimulation of thyroid stimulating hormone was also increased in contrast with increased production of PRL. So, by the increased production of PRL fertility rate of reproductive females altered by the impairment in the GnRH pulsatile and finally affect ovarian function in the study of Kris Poppe, *et al.*, in 2007. Our present study was also followed through this statement because many reproductive females who affected through hypothyroidism had history of menstrual irregularities and ultimately infertility.

The pregnant females who took part in our study that came for routine checkup during pregnancy. Some of them were also affected through hypothyroidism and their prevalence rate was less in comparison from other two groups. Pregnant females also seen to affect with hyperthyroidism but its prevalence was very less in comparison to hypothyroidism. Evaluation of thyroid hormones in pregnancy is necessary because hypothyroidism causes complication to the pregnant females like intellectual impairment to the fetus. In the first trimester of pregnancy fetus central nervous start developing, during this stage maternal thyroid hormones is necessary because fetus thyroid gland not able to synthesize thyroid hormones at this stage according to the study of Brain M. Casey *et al.*, So, in our study normal level of T<sub>3</sub>, T<sub>4</sub> and TSH was evaluated in the pregnant females (table 2) to see any impairment in the level of thyroid hormones thus protecting the any abnormalities to the fetus life. Most of the females were found with normal level of all of these hormones in our study.

In our study very less menopausal female participated as comparison to pregnant and reproductive female. This may be due to absence of symptoms of hypothyroidism in older people or symptoms of thyroid disorder somewhat similar with ageing process according to

the study of Mustuko Nagata. *et.al*, Menopausal females were also affected through hypothyroidism in our study but its prevalence was higher than pregnant female and lesser than reproductive female. Some of these female also affected through hyperthyroidism. Prevalence of hypothyroidism in this group was also high in comparison to hyperthyroidism. According to study of Mustuko Nagata.*et.al*In case of hypothyroidism affected menopausal female level of thyroid hormones decrease thus reduction in oestoblastic and bone differentiation process. Ultimately both the level of bone formation and bone reabsorbtion start reducing but in our study there was not any kind of bone abnormalities in comparison with thyroid disorder seen. The level of thyroid stimulating hormone increase in case of clinical hypothyroidism with decrease level of T<sub>3</sub> and T<sub>4</sub> and in subclinical finding the level of TSH increase but T<sub>3</sub> and T<sub>4</sub> remain normal. In our study the level of TSH in hypothyroid menopausal female was much high in comparison to pregnancy and reproductive. The reason behind was the lack of diagnosis of thyroid disorder at initial stage in menopausal females.

Pregnant female were often screened through thyroid profile to evaluate normal function of thyroid gland to overcome the need of thyroid hormone for fetus brain development. Reproductive female generalize the symptoms of menstrual irregularities to evaluate the cause of menstrual irregularities these females were also screened through thyroid profile. Thus in the initial stage these two groups screened but menopausal female not screened at initial stage. So level of TSH in subclinical hypothyroid menopausal female was higher than other two group in our finding (figure10). Prevalence of hypothyroidism found higher in reproductive females as comparison to other two groups (figure 11) This is due to numerous interaction of thyroid hormone with normal reproductive function both by directly affecting the function of ovaries or indirectly by interacting with sex hormone binding proteins. Further this work need more sample size and statistical analysis to give a scientific judgement and stating the exact evaluation of thyroid dysfunction in different stages of females.



## **Conclusion**

In our present study, the prevalence of thyroid dysfunction was high in Reproductive stage of females as compared to other two groups viz. Pregnant and Menopausal Females. These females presented the symptoms of menstrual irregularities. Most of the pregnant females who participated in the study were having normal level Thyroid Profile. In case of menopausal females there were very few patients screened for thyroid profile as the symptoms of thyroid dysfunction were similar to ageing, like fatigue, tiredness, lack of concentration and dry skin. Although very less menopausal female were screened than other two groups but prevalence of thyroid dysfunction was higher than pregnant females but lesser than reproductive females. In case of menopausal females who were affected with subclinical hypothyroidism the level of TSH was much higher than other two groups. This is due to screening process delay due to paucity of symptoms. Further studies work required more sample size and long term follows up to confirm the variation in TSH level in different females.

**CHAPTER 7**

---

---

References

---

---

## **Bibliography**

- [1] S. Reza. (2011) Basic Human Anatomy and Physiology, Mediaplex publisher & Distributor: Dhaka, pp. 193.
- [2] W.F. Ganong. (2011) The Thyroid Gland in Review of Medical Physinology, The McGraw Hill Companies: Newyork, pp. 307.
- [3] I.E. Griffin and S. R. Objeda. (1988). The Textbook of Endocrine Physiology, New York: Oxford University Presspp. 222 – 232.
- [4] T.E. Andreali, C.C. Bannet, F.C. Plum, Plum. (1997). Textbook of Medicine, 4th Edition, Philadelphia: Saunder& Co, p.952–953.
- [5] R.K. Murry, P.K. Gerner, P.A. Mays, V.W. Harper's Rodwel. (2000). Textbook of Biochemistry, 25th Edition, Appleton & Lange:Stanford, pp. 8.
- [6]. Unnikrishnan AG, Menon UV. (2011). Thyroids disorders in India: An epidemiological perspective. Indian J Endocrinology Metab, 15(s), 78- 81. |
- [7]. Larsen PR, Davies TF, Hay ID. (1998). The thyroid. In: Williams RH, Wilson JD, Foster DW, Kronenberg HM, editors. Williams Textbook of Endocrinology. 9th ed. Philadelphia: Saunders, 389-416.
- [8]Kochupillai N. (2000). Clinical endocrinology in india. Curr. Sci., 79, 1061-1067.
- [9]Landenson PW, Singer PA, Ain KB. (2000). American thyroid association guide-lines for detection of thyroid dysfunction. Arch Intern Med, 160, 1573-75.
- [10] De Escobar G. Morreale.(2001) “The role of thyroid hormone in fetal neurodevelopment” J. Pediatr.EndocrinolMetab., , vol. 14, No. (Suppl 6), pp. 1453-1462.
- [11] De Escobar G. Morreale, M. J. Obregon and del Rey F. Escobar. (2000) “Is neuropsychological development related to maternal hypothyroidism or to maternal hypothyroxinemia?”J. Clin. EndocrinolMetab., , vol. 85, pp. 3975-3987.
- [12] G. Mirabella, D. Feig, E. Astzalos, K. Perlman and J.F. Rovet.(2000) “The effect of abnormal intrauterine thyroid hormone economies on infant cognitive abilities” J. Pediatr.EndocrinolMetab., vol. 13, pp. 191-194.
- [13] A.L. Dowling, E.A. Iannacone and R.T. Zoeller. (2001). Maternal hypothyroidism selectively affects the expression of neuroen-docrine-specific protein a messenger ribonucleic acid in the proliferative zone of the fetal rat brain cortex” Endocrinologyvol. 142, pp. 390-399.
- [14] P.A. Piosik, M. van Groenigen, J. van Doorn, F. Baas and J. J. de Vijlder.(1997). “Effects of maternal thyroid status on thyroid hormones and growth in congenitally hypothyroid goat fetuses during the second half of gestation endocrinologyvol. 138, pp. 5-11.

- [15] X. Y. Cao, X. M. Jiang, Z. H. Dou, M. A. Rakeman, M. L. Zhang, K. O'Donnell, T. Ma, K. Amette, N. DeLong and G.R. DeLong. (1994). "Timing of vulnerability of the brain to iodine deficiency in endemic cretinism" *N. Engl. J. Med.*, vol.331, pp. 1739-1744.
- [16] T. Vulsmä, M. H. Gons and J. J. de Vijlder. (1989) "Maternal-fetal transfer of thyroxine in congenital hypothyroidism due to a total organification defect or thyroid agenesis" *N. Engl. J. Med.*, , vol. 321, pp. 13-16.
- [17] Constance M. Lebrun, et al., (2013) *Effects of Female Reproductive Hormones on Sports Performance*. Springer Science+Business. DOI 10.1007/978-1-62703-314-5\_16
- [18]. Janse de Jonge XA.(2003)"Effects of the menstrual cycle on exercise performance. *Sports Med.*;33(11):833–51.
- [19]. Vanheest JL, Mahoney CE, Rodgers CD. (2005). Oral contraceptive use and physical performance . *The endocrine system in sports and exercise*. In: Kraemer WJ, Rogol AD, editors. *The encyclopaedia of sports medicine—an IOC Medical Commission Publication*. Malden, MA: Blackwell Publishers; p. 250–60
- [20] Wang, C. & Crapo, L.M. (1997) The epidemiology of thyroid disease and implications for screening. *Endocrinology and Metabolism Clinics of North America*, 26, pp 189–218
- [21] Bjoro, T., Holmen, J., Kruger, O., Midthjell, K., Hunstad, K., Schreiner, T., Sandnes, L. & Brochmann, H. (2000) Prevalence of thyroid disease, thyroid dysfunction and thyroid peroxidase antibodies in a large, unselected population. *The Health Study of Nord-Trøndelag (HUNT)*. *European Journal of Endocrinology*, 143, pp 639–64
- [22] Benson, R.C. & Dailey, M.E. (1955) The menstrual pattern in hyperthyroidism and subsequent posttherapy hypothyroidism. *Surgery, Gynecology and Obstetrics*, 100, pp19–26
- [23] Goldsmith, R.E., Sturgis, S.H., Lerman, J. & Stanbury, J.B. (1952) The menstrual pattern in thyroid disease. *Journal of Clinical Endocrinology and Metabolism*, 12, pp 846–855
- [24] Osathanondh R, Tulchinsky D, Chorpa IJ (1976). Total and free thyroxine and triiodothyronine in normal and complicated pregnancy. *J. Clin. Endocrinol. Metab.* 42: pp98-104
- [25] Glinoe D (2000). Thyroid immunity, thyroid dysfunction and the risk of miscarriage. *Am. J. Reprod. Immunol.* 43: pp202-203.
- [26] Kuroka H, Takahashi K (2005). Maternal thyroid function during pregnancy and puerperal. *Endo. J.* 52: 587-591
- [27] Imaizumi M, Pritzker A, Kita M, Ahmad L, Unger P, Davies T (2001). Pregnancy and murine thyroiditis: Thyroglobulin immunization leads to fetal loss in specific allogeneic pregnancies. *Endocrinology.* 142: 823-823

- [28]Glinoeer D (2004). Increased TBG during pregnancy and increased hormonal requirements. *Thyroid*. 14: 479-480
- [29] Zigman JM, Cohen SE, Graber JF (2003). Impact of thyroxine-binding globulin on thyroid hormone economy during pregnancy. *Thyroid*, 13: 1169-1175
- [30]Sioba'n D. Harlow, PhD, Margery Gass MD, NCMP, Janet E. Hall, MD, 3 Roger Lobo, MD, 4 Pauline Maki, PhD (2012) Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging: "Menopause: The Journal of The North American Menopause Society" Vol. 19, No. 4, pp.2-9
- [31]. Johannes CB, Crawford SL, Longcope C, McKinlay SM. (1996) " Bleeding patterns and changes in the perimenopause: a longitudinal characterization of menstrual cycles". *Clin Consult ObstetGyncecol* 8:9-20.
- [32]. Mitchell ES, Woods NF, Mariella A. (2000). Three stages of the menopausal transition from the Seattle Midlife Women's Health Study: toward a more precise definition. *Menopause*;7: pp.334-349.
- [33]. Van Voorhis BJ, Santoro N, Harlow S, Crawford SL, Randolph J. (2008) "The relationship of bleeding patterns to daily reproductive hormones in women approaching menopause." *Obstet Gynecol*;112:101-108
- [34]. Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. (2000) "A prospective population-based study of menopausal symptoms". *Obstet Gynecol*;96: pp351-358
- [35]. Dennerstein L, Dudley E, Burger H. (2001). "Are changes in sexual functioning during midlife due to aging or menopause?" *Fertil Steril*;76:456-460.
- [36]. Woods NF, Mitchell ES. (2005) "Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women's lives". *Am J Med*;pp118:14-24.
- [37]. Hall JE. (2004) "Neuroendocrine physiology of the early and late menopause." *EndocrinoMetabClin North Am*;33:pp637-659.
- [38]. Hall JE, Lavoie HB, Marsh EE, Martin KA. (2000) "Decrease in gonadotropinreleasing hormone (GnRH) pulse frequency with aging in postmenopausal women." *J ClinEndocrinol Metab*;85:pp1794-1800.
- [39]. Mahmud K (2010) "Natural hormone therapy for menopause. *Gynecological Endocrinology*" (vol26): pp81-85.
- [40]. Diamanti-Kandarakis E, Lambrinoudaki I, Economou F, Christou M, Piperi C, et al. (2010) Androgens associated with advanced glycation end-products in postmenapausal women. *Menopause* 17: pp1-5.

- [41]. O'Connor KA, Ferrell R, Brindle E, Trumble B, Shofer J, et al. (2009) Progesterone and ovulation across stages of the transition to menopause. *Menopause* 16: pp1178–87.
- [42]. Panay N, Al-Azzawi F, Bouchard C, Davis SR, Eden J, et al. (2010) Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. *Climacteric* 13: pp121–31.
- [43]. Berent-Spillson A, Persad CC, Love T, Tkaczyk A, Wang H, et al. (2010) Early menopausal hormone use influences brain regions used for visual working memory. *Menopause* 17: pp692–9.
- [44]. Newhouse PA, Dumas J, Wilkins H, Coderre E, Sites CK, et al. (2010) Estrogen treatment impairs cognitive performance after psychosocial stress and monoamine depletion in postmenopausal women. *Menopause*. 17:pp 860–73.
- [45]. Lord C, Engert V, Lupien SJ, Pruessner JC (2010) Effect of sex and estrogen therapy on the aging brain: a voxel-based morphometry study. *Menopause* 17:pp 846–51.
- [46]. Wiacek M, Hagner W, Zubrzycki IZ (2010) Measures of menopause driven differences in levels of blood lipids, follicle-stimulating hormone, and luteinizing hormone in women aged 35 to 60 years: National Health and Nutrition Examination Survey III and National Health and Nutrition Examination . *Menopause* 18: pp1–7.
- [47]. Bryan KJ, Mudd JC, Richardson SL, Chang J, Lee HG, et al. (2010) Downregulation of serum gonadotropins is as effective as estrogen replacement at improving menopause-associated cognitive deficits. *J Neurochem* 112: pp870–81.
- [48]. Ka° ss AS, Lea TE, Torjesen PA, Gulseth HC, Førre ØT (2010) The association of luteinizing hormone and follicle-stimulating hormone with cytokines and markers of disease activity in rheumatoid arthritis: a case-control study. *Scand J Rheumatol* 39: pp109–17.
- [49]. Davis JD, Podolanczuk A, Donahue JE, Stopa E, Hennessey JV, et al. (2008) Thyroid hormone levels in the prefrontal cortex of post-mortem brains of Alzheimer's disease patients. *Curr Aging Sci* 1: pp175–81.
- [50]. So"zay S, Go"kc,e-Kutsal Y, Celiker R, Erbas T, Bas,go"ze O(1994) Neuroelectrophysiological evaluation of untreated hyperthyroid patients. *Thyroidology* 6:pp55–9.
- [51] Sapin R, Schlienger JL (2003). Thyroxine (T4) and triiodothyronine (T3) determinations: techniques and value in the assessment of thyroid function. *Ann. Biol. Clin. (Paris)*. 61 :pp 411-420.
- [52] S. Glick. "Rosalyn sussmanyalow (1921–2011)" *Nature*, 2011, vol. 474 (7353), pp. 580.
- [53] Tseng F, Lin W, Lin C, et al. *J Am CollCardiol* 2012 ;60(8):730-737

- [54]Etkin, W.&Gona, A. G. (1974). Evolution of thyroid function in poikilothermic vertebrates. In Handbook of Physiology. Section 7, volume III, Thyroid (eds. M. A. Greer & D. H. Solomon), American Physiological Society, Washington, DC. pp. 5±20
- [55]Eales, J. G. (1997). Iodine metabolism and thyroid-related functions in organisms lacking thyroid follicles : are thyroid hormones also vitamins? Proceedings of the Society for Experimental Biology and Medicine **214**, 302±317
- [56]Gemmill, C. L. (1955). The apparent ionization constants of the phenolic hydroxyl groups of thyroxine and related compounds. Archives of Biochemistry & Biophysics 54, 359±367.
- [57]Hillier, A. P. (1970). The binding of thyroid hormones to phospholipid membranes. Journal of Physiology **211**, 585±597
- [58] Boelaert K, Franklyn JA. (2005) “Thyroid hormone in health and disease. J Endocrinol” 187:pp1-15
- [59]Yen PM. (2001) “Physiological and molecular basis of thyroid hormone action”. Physiol Rev;81:pp1097-142.
- [60]Malik R, Hodgson H. (2002). The relationship between the thyroid gland and the liver. QJM;95:pp559-69
- [61]Youssef WI, Mullen KD. (2002). The liver in other (nondiabetic) endocrine disorders. Clin Liver Dis;6:pp879-89.
- [62]J.W. Smith, A.T. Evans, B. Costall, J.W. Smythe, (2002) Thyroid hormones, brain function and cognition: a brief review. Neurosci. Biobehav. Rev. 26, 45–60
- [63]P. Kaminsky, M. Klein, M. Duc, (1992) “Hypothyroid myopathy—physiopathological approach”. Ann. Endocrinol. 53, pp 125–132
- [64] G. Vitale, S. Salvioli, C. Franceschi, (2013) “Oxidative stress and the ageing endocrine system.” Nat. Rev. Endocrinol. 9, 228–240
- [65]G.P. Bianchi, V. Zaccheroni, E. Solaroli, F. Vescini, R. Cerutti, M. Zoli, G. Marchesini, Health-related quality of life in patients with thyroid disorders. Qual. Life Res. 13, 45–54 (2004)
- [66]. S. Gulseren, L. Gulseren, Z. Hekimsoy, C. Ozen, B. Tokatlioglu, (2006) “Depression, anxiety, health-related quality of life, and disability in patients with overt and subclinical thyroid function” Arch. Med. Res. 37, pp133–139

- [67]. A. MouraNeto, M.C. Parisi, M.A. Tambascia, E.J. Pavin, S.M. Alegre, D.E. Zantut-Wittmann, (2013). Relationship of thyroid hormone levels and cardiovascular events in patients with type 2 diabetes. *Endocrine* doi:10.1007/s12020-013-0038-6
- [68]Kochupillai N. (2000); *Clinical Endocrinology in India.Curr Sci.* 79(10):pp1061-1067.
- [69]. Delang F.(1994); “The Disorder induced by iodine deficiency”. *Thyroid*4:pp107-28.
- [70]. Cooper DS. Subclinical Hypothyroidism. (2000). *N. Eng. J:Med*, 345(4),pp260-265
- [71].GiampaoloPapi , Salvatore Maria Corsello and Alfredo Pontecorvi(2014)*Clinical concepts on thyroid emergencies; (vol 5),pp 102-111*
- [72].PapiG,PearceEN,BravermanLE,BetterleC,Roti E. (2005)“ A clinical and therapeutic approach to thyrotoxicosis with thyroid- stimulatinghormon esuppression only”. *AmJMed***118**:pp349–61.doi
- [73].BolaertK,FranklynJA. (2005)“Thyroidhormoneinhealthanddisease”.*Endocrinol***187**:pp1–15
- [74]. Knudson PB. (1995) Hyperthyroidism in adults: variable clinical presentations and approaches to diagnosis. *J Am Board Fam Pract*;8:109-13
- [75]. Fitzgerald PA. (2005) *Endocrinology*. In: Tierny LM, McPhee SJ, Papadakis MA, eds. *Current medical diagnosis and treatment*. 44th ed. New York: McGraw-Hill,;pp1102-10
- [76] Woeber KA. (2000); Update on the management of hyperthyroidism and hypothyroidism. *Arch Intern Med* 160:pp1067-71
- [77]. Corvilain B, Dumont JF, Vassart G. Toxic adenoma and toxic multinodular goiter. In: Werner SC, Ingbar SH, Braverman LE, Utiger RD, eds. *Werner &Ingbar’s (2000) “The thyroid: a fundamental and clinical text*. 8th ed. Philadelphia: Lippincott Williams & Wilkins”:564-72
- [78]BiondiB,CooperDS.Theclinicalsignificanceofsubclinicalthyroiddysfunction. *EndocrRev*(2008) **29**:76–131.doi:10.1210/er.2006-0043
- [79]Bhutta AT, Cleves MA, Casey PH, Cradock MM, Anand KJ. (2002) Cognitive and behavioral outcomes of school-aged children who were born preterm: a meta-analysis. *JAMA*;288:pp728 –37.
- [80]. Poppe K, Velkeniers B, Glinde D. (2008). The role of thyroid autoimmunity in fertility and pregnancy. *Nat ClinPractEndocrinolMetab.* ;pp4:394–405
- [81]. Poppe K, Velkeniers B. (2003). Thyroid disorders in infertile women. *Ann Endocrinol.* ;64:pp45–50.



- [82]. Akhter N, Hussan SA. (2009) “ Subclinical hypothyroidism and hyper prolactinemia in infertile women: Bangladesh perspective after universal salt iodination”. [Last accessed on 2011 Aug 16];Internet J Endocrinol (vol5)
- [83]. Lincoln R, Ke RW, Kutteh WH. (1999) “Screening for hypothyroidism in infertile women.” J Reprod Med;44:pp455–7.
- [84]. Krassas GE. (2000) Thyroid disease and female reproduction. FertilSteril. ;74:pp1063–70.
- [85]. Anderson S, Pederson KM, Bruun NH, LaurbergP .(2002) “Narrow individual variations in serum T4 and T3 in normal subjects; a clue to the understanding of subclinical thyroid disease. J ClinEndocrinol Metab;87:pp1068–72.
- [86]. Raber W, Gessl A, Nowotny P, Vierhapper H. (2003) “Hyperprolactnemia in hypothyroidism; clinical significance and impact of TSH normalization”. ClinEndocrinol. ;58:pp185–91.
- [87]. Olivar AC, Chaffkin LM, Kates RJ, Allan TR, Beller P, Graham NJ. (2003); “ Is it necessary to obtain serum levels of thyroid stimulating hormone and prolactin in asymptomatic women with infertility?” Conn Med67:pp393–5.
- [88]. Davis LB, Lathi RB, Dahan MH. (2007) “The effect of infertility medication on thyroid function in hypothyroid women who conceive”. Thyroid. ;17:773–7
- [89]. Dajan CM, Saravanan P, Bayly G. .(2002) “Whose normal thyroid function is better – yours or mine? Lancet”;360:pp353–4.
- [90]Vanderpump, M.P., Tunbridge, W.M., French, J.M., Appleton, D., Bates, D., Clark, F., Grimley Evans, J., Hasan, D.M., Rodgers, H. & Tunbridge, F. (1995) The incidence of thyroid disorders in the community: a twenty-year follow-up of the Wickham Survey. Clinical Endocrinology, 43, pp55–68
- [91] Hollowell, J.G., Staehling, N.W., Flanders, W.D., Hannon, W.H., Gunter, E.W., Spencer, C.A. & Braverman, L.E. (2002) Serum TSH, T(4), and thyroid antibodies in the United States
- [92] Longcope, C., Abend, S., Braverman, L.E. & Emerson, C.H. (1990) Androstenedione and estrone dynamics in hypothyroid women. Journal of Clinical Endocrinology and Metabolism, 70,pp 903–907

- [93] Scanlon, M.F., Chan, V., Heath, M., Pourmand, M., RodriguezArnao, M.D., Weightman, D.R., Lewis, M. & Hall, R. (1981) Dopaminergic control of thyrotropin, alpha-subunit, thyrotropin beta-subunit, and prolactin in euthyroidism and hypothyroidism: dissociated responses to dopamine receptor blockade with metoclopramide in hypothyroid subjects. *Journal of Clinical Endocrinology and Metabolism*, 53, pp360–365
- [94] Thomas, R. & Reid, R.L. (1987) Thyroid disease and reproductive dysfunction: a review. *Obstetrics and Gynecology*, 70, pp789–798.
- [95] Wakim, A.N., Polizotto, S.L., Buffo, M.J., Marrero, M.A. & Burholt, D.R. (1993) Thyroid hormones in human follicular fluid and thyroid hormone receptors in human granulosa cells. *Fertility and Sterility*, 59, pp1187–1190
- [96] Cecconi, S., Rucci, N., Scaldaferrri, M.L., Masciulli, M.P., Rossi, G., Moretti, C., D'Armiento, M. & Ulisse, S. (1999) Thyroid hormone effects on mouse oocyte maturation and granulosa cell aromatase activity. *Endocrinology*, 140, pp1783–1788
- [97] Maruo, T., Matsuo, H. & Mochizuki, M. (1991) Thyroid hormone as a biological amplifier of differentiated trophoblast function in early pregnancy. *Acta Endocrinologica*, 125, 58–66
- [98] Ansell, J.E. (1996) The blood in the hypothyroidism. In: L. Braverman, R. Utiger eds. *Werner and Ingbar's the Thyroid: A Fundamental and Clinical Text*, 7th edn. Lippincott-Raven, Philadelphia, 821–825
- [99] Krassas, G.E. (2000) Thyroid disease and female reproduction. *Fertility and Sterility*, 74, 1063–1070
- [100] Tanaka, T., Tamai, H., Kuma, K., Matsuzuka, F. & Hidaka, H. (1981) Gonadotropin response to luteinizing hormone releasing hormone in hyperthyroid patients with menstrual disturbances. *Metabolism*, 30, 323–326
- [101] Goldsmith, R.E., Sturgis, S.H., Lerman, J. & Stanbury, J.B. (1952) The menstrual pattern in thyroid disease. *Journal of Clinical Endocrinology and Metabolism*, 12, 846–855.
- [102] Joshi, J.V., Bhandarkar, S.D., Chadha, M., Balaiah, D. & Shah, R. (1993) Menstrual irregularities and lactation failure may precede thyroid dysfunction or goitre. *Journal of Postgraduate Medicine*, 39, pp137–141.

- [103] Tomer, Y., Barbesino, G., Greenberg, D.A. & Davies, T.M. (2002) The genetics of the autoimmune thyroid disease. In: J.D. Baxter ed. *Genetics in Endocrinology*. Lippincott Williams and Wilkin's, Philadelphia.
- [104] Weetman, A.P. (2004) Cellular immune responses in autoimmune thyroid disease. *Clinical Endocrinology*, 61, 405–413.
- [105] Ando, T. & Davies, T.F. (2004) Self-recognition and the role of fetal microchimerism. *Best Practice and Research. Clinical Endocrinology and Metabolism*, 18, pp197–211.
- [106] Prummel, M.F., Strieder, T. & Wiersinga, W.M. (2004) The environment and autoimmune thyroid diseases. *European Journal of Endocrinology*, 150, pp 605–618
- [107] Shiozawa, T., Shih, H.C., Miyamoto, T., Feng, Y.Z., Uchikawa, J., Itoh, K. & Konishi, I. (2003) Cyclic changes in the expression of steroid receptor coactivators and corepressors in the normal human endometrium. *Journal of Clinical Endocrinology and Metabolism*, 88, pp 871–878.
- [108] Alarid, E.T., Preisler-Mashek, M.T. & Solodin, N.M. (2003) Thyroid hormone is an inhibitor of estrogen-induced degradation of estrogen receptor-alpha protein: estrogen-dependent proteolysis is not essential for receptor transactivation function in the pituitary. *Endocrinology*, 144, pp3469–3476.
- [109] Abalovich et al., (2007) “Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline”. *J Clin Endocrinol Metab*. Aug;92(8 Suppl):S1-47.
- [110]. Brian M. Casey, MD, Jodi S. Dashe, MD, C. Edward Wells, MD, Donald D. McIntire, PhD, William Byrd, PhD, Kenneth J. Leveno, MD, and F. Gary Cunningham, MD (2005) “Subclinical Hypothyroidism and Pregnancy Outcomes” Vol 1105, by The American College of Obstetricians and Gynecologists.
- [111] Pharoah POD, Connolly KJ, Ekins RP, Harding AG. (1984) “Maternal thyroid hormone levels in pregnancy and the subsequent cognitive and motor performance of the children.” *Clin Endocrinol (Oxf)*; 21: pp265-70.
- [112]. JAMES E. H Addow, M.D., Glenn E. Palomaki, B.S., et al. (1999) “Maternal Thyroid Deficiency during pregnancy and subsequent neurological development of the child” *The New England Journal of Medicine*. 341(8): pp549-555

- [113].Sutherland JM, Esselborn VM, Burket RL, Skillman TB, Benson JT. (1960) “Familial nongoitrous cretinism apparently due to maternal antithyroid antibody: report of a family.” *N Engl J Med*;263:pp336-41.
- [114].Connors HM, Styne DM. (1986) “Transient neonatal “athyreosis” resulting from thyrotropin- binding inhibitory immunoglobulins”. *Pediatrics*; 78: pp287-90.
- [115].Cho BY, Shong YK, Lee HK, Koh CS, Min HK, Lee M. (1988) “Transient neonatal hypothyroidism due to transplacental transfer of maternal immunoglobulins that inhibit TSH binding, TSH-induced cAMP increase and cell growth”. *Endocrinol Jpn*;35:pp819-26.
- [116].Fort P, Lifshitz F, Pugliese M, Klein I. (1988) “Neonatal thyroid disease: differential expression in three successive offspring”. *J ClinEndocrinol Metab*;66:pp645-7.
- [117].Goldsmith RE, McAdams AJ, Larsen PR, McKenzie M, Hess EV. (1973) “Familial autoimmune thyroiditis: maternal-fetal relationship and the role of generalized autoimmunity”. *J ClinEndocrinol Metab*;37:pp265-75.
- [118].Man EB, Jones WS. (1969) “Thyroid function in human pregnancy. V. Incidence of maternal serum low butanol-extractable iodines and of normal gestational TBG and TBPA capacities: retardation of 8-month-old infants”. *Am J Obstet Gynecol*;104:pp898-908.
- [119]. Dussault JH, Fisher DA. (1999) “Thyroid function in mothers of hypothyroid newborns. *Obstet Gynecol*”;93:pp15-20.
- [120]. Utiger RD. (1999) “Maternal hypothyroidism and fetal development”. *N Engl J Med*;341:pp601– 02.
- [121]. Xue-Yi C, Xin-Min J, Zhi-Hong D, Rakeman MA, Ming-Li Z, O’Donnell K, et al. (1994); “Timing of vulnerability of the brain to iodine deficiency in endemic cretinism”. *N Engl J Med* 331:pp1739–44.
- [122]. DeLong GR, Stanbury JB, Fierro-Benitez R. (1985) “Neurological signs in congenital iodine-deficiency disorder. *Dev Med Child Neurol*”;27:pp317–24.
- [123]Davis LE, Leveno KJ, Cunningham FG.(1988) Hypothyroidism complicating pregnancy.*Obstet Gynecol*;72: 108–12.
- [124]Leung AS, Millar LK, Koonings PP, Montoro M, MestmanJH.Perinatal outcome in hypothyroid pregnancies.*ObstetGynecol* 1993;81:349 –53.
- [125]. Cooper DS. (2001)Subclinical hypothyroidism. *N Engl J Med*;345:pp260 –5.
- [126]. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, et al. (2004) “Subclinical thyroid disease: scientific review and guidelines for diagnosis and management”. 291:pp228 –38.

- [127]. Klein RZ, Haddow JE, Faix JD, Brown RS, Hermos RJ, Pulkkinen A, et al. Prevalence of thyroid deficiency in pregnant women(1991). *ClinEndocrinol (Oxf)*;35:pp41– 6.
- [128]. Woeber KA.(1997) “Subclinical thyroid dysfunction. *Arch Intern Med*;157:1065– 8.
- [129]. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC.(2000) “The Colorado thyroid disease prevalence study”. *Arch Intern Med*;160:pp526 –34.
- [130] Maruo, T., Katayama, K., Matuso, H., Anwar, M. & Mochizuki, M. (1992) “The role of maternal thyroid hormones in maintaining early pregnancy in threatened abortion”. *ActaEndocrinologica*, 127,pp 118– 122.
- [131] Robbins J (1981).Factors altering thyroid hormone metabolism. *Environ Health Perspect.* 38: 65-70.
- [132] Guillaume J, Schussler GC, Goldman J (1985). Components of the total serum thyroid hormone concentrations during pregnancy: high free thyroxine and blunted thyrotropin (TSH) response to TSHreleasing hormone in the first trimester. *J. Clin. Endocrinol. Metab.*60: pp678-684.
- [133] Vieira JG, Kanashiro I, Tachibana TT, Ghiringhello MT, Hauache OM, Maciel RM. (2004) Free thyroxine values during pregnancy. *Arq Bras Endocr.Metabol*; 48: 305-309
- [134] Lapko AG, Golovaty AS, Ermolenko MN, Milyutin AA (2000).Thyroxine-binding globulin as an indicator of body exposure to unfavorable environmental factors. *Bull. Exp. Biol. Med.* 129: pp163-167.
- [135]Ardawi MS, Nasrat HA, Mustafa BE (2002). Urinary iodine excretion and maternal thyroid function. During pregnancy and postpartum.*Saudi. Med. J.* 23: 413-422.
- [136] Winkler AW, Criscuolo J, Laviates PH (1943).Quantitative relationship between basal metabolic rate and thyroid dosage in patients with true myxedema. *J. Clin. Invest.* 22: pp531-534
- [137]LeBeauSO, Mandel SJ (2006).Thyroid disorder during pregnancy. *Endocrinol, Metab.Clin. North Am.* 35: pp117-136.
- [138] Springer D, Zima T, Limanova Z (2009). Reference intervals in evaluation of maternal thyroid function during the first trimester of pregnancy. *Eur. J. Endocrinol.* 160: pp791-797.
- [139] Hallengren B, Mlantz B, Andreasson L, Grennert L (2009). Pregnant women on thyroid substitution are often dysregulated in early pregnancy. *Thyroid.* 19: pp391-394.
- [140]Gibbs RB (2010) Estrogen therapy and cognition: a review of the cholinergic hypothesis. *Endocr Rev* 31: 224–53.
- [141]. Lord C, Engert V, Lupien SJ, Pruessner JC (2010) Effect of sex and estrogen therapy on the aging brain: a voxel-based morphometry study. *Menopause* 17: 846–51.

- [142]. Wiacek M, Hagner W, Zubrzycki IZ (2010) Measures of menopause driven differences in levels of blood lipids, follicle-stimulating hormone, and luteinizing hormone in women aged 3 to 60 years: National Health and Nutrition Examination Survey III and National Health and Nutrition Examination Survey 1999–2002 study. *Menopause* 18: 1–7.
- [143]. Bryan KJ, Mudd JC, Richardson SL, Chang J, Lee HG, et al. (2010) Downregulation of serum gonadotropins is as effective as estrogen replacement at improving menopause-associated cognitive deficits. *J Neurochem* 112: 870–81.
- [144]. Ka° ss AS, Lea TE, Torjesen PA, Gulseth HC, Førre ØT (2010) The association of luteinizing hormone and follicle-stimulating hormone with cytokines and markers of disease activity in rheumatoid arthritis: a case-control study. *Scand J Rheumatol* 39: 109–17.
- [145] Cham M, Chow C, Hamson DK, Lieblich SE, Galea LA (2014) Effects of chronic estradiol, progesterone and medroxyprogesterone acetate on hippocampal neurogenesis and adrenal mass in adult female rats. *J Neuroendocrinol* doi: 10.1111/jne.12159.
- [146] Wira CR, Fahey JV, Rodriguez-Garcia M, Shen Z, Patel MV (2014) Regulation of mucosal immunity in the female reproductive tract: the role of sex hormones in immune protection against sexually transmitted pathogens. *Am J Reprod Immunol* doi: 10.1111/aji.12252.
- [147] Pantazi H, Papapetrou PD (2000) Changes in parameter of bone and mineral therapy during therapy for hyperthyroidism. *J Clin Endocrinol Metab* 85: pp1.99-1106
- [148] Painter SE, KLEEREKOPER M, Camacho PM (2006) secondary osteoporosis a review of the recent evidence *Endocr Pract* 12:436-445
- [149] Suzuki A, Kotake M, Ono Y, Katko T, et al. (2006) “Vitamin D in type 2 diabetes mellitus: association with microvascular complication and treatment. *Endocr J* 53: pp50-510.
- [150] Conidre JM, David JP, Rivere I., Gourssot JF, Roger P, de Mascarel A, Meunier PJ (1986) “Bone loss in hypothyroidism with hormone replacement A histomorphometric study. *Arch Intern Med* 146: pp48- 53
- [151] Eriksen EF (1986) Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of metabolic bone disease. *Endocr Rev* 7: pp379-408
- [152] Vestergaard P, Mosekilde L (2002) fracture in patients in hypothyroidism; a nationwide follow-up study in 16,249 patients. *Thyroid* 12: pp411-419
- [153] Woeber KA (1997) subclinical thyroid dysfunction *Arch Intern Med* 157: pp1065-1068
- [154] Wilson S, Parle JV, Roberts LM, Roalfe AK, Hobbs FD, Clark P, Sheppard MC Team (2006) Prevalence of subclinical thyroid dysfunction and its relation to socioeconomic deprivation in the elderly; *J Clin Endocrinol Metab* 91: pp4809-4816

- [155] Abe E, Mariani RC, Yu W, Ando T, Li Y, Iqbal J, Eldeiry L, Ranjendren G, Blair HC, Davis TF, Zaidi M (2003) TSH is a negative regulator of skeletal remodeling. *Cell* 115: 151-162
- [156] Chen GG, Vlantis AC, Zeng Q, van Hasselt CA. (2008) "Regulation of cell growth by estrogen signaling and potential targets in thyroid cancer". *Current Cancer Drug Targets*; 8:pp367–77.
- [157]. Rajoria S, Suriano R, Shanmugam A, Wilson YL, Schantz SP, Geliebter J, et al. (2010) "Metastatic phenotype is regulated by estrogen in thyroid cells". *Thyroid*; 20:33–41.
- [158] Nils Knudsen Inge BuÈlow, Torben Jørgensen, Peter Laurberg, Lars Ovesen and Hans Perrild ((2000) "Comparative study of thyroid function and types of thyroid dysfunction in two areas in Denmark with slightly different iodine status" *European Journal of Endocrinology* (vol-143) pp 485-491
- [159] Dilutpal Sharma, Amit Vasant Deshpande, Naved Ahmad and Akash Gupta (2014) "Thyroid Disorders in Greater Noida: A hospital based study" *International Journal of Biomedical Research* Vol 5 pp 274-276
- [160]. Ines Donangelo, MD, PhD, and Glenn D. Braunstein, MD, (2011) "Update on Subclinical Hyperthyroidism", *American Family Physician* Volume 83, Number 8 pp 933-938
- [161] Isabela M. Benseñor, Alessandra Carvalho Goulart, Paulo A. Lotufo, Paulo Rossi Menezes, Marcia Scazufca (2011) Prevalence of thyroid disorders among older people: results from the São Paulo Ageing & Health Study; *AGEING AND THYROID DISORDERS* 27(1):pp 155-161
- [162] Mirella P. Hage and Sami T. Azar (2011) The Link between Thyroid Function and Depression: *Journal of Thyroid Research* vol (2012) pp 2-8
- [163] Emmy van den Boogaard, Rosa Vissenberg, Jolande A. Land, Madelon van Wely, Joris A.M. van der Post, Mariette Goddijn, and Peter H. Bisschop (2011) Significance of (sub)clinical thyroid dysfunction and thyroid autoimmunity before conception and in early pregnancy: a systematic review, *Human Reproduction Update*, Vol.17, No.5 pp. 605–619,
- [164] Alhamd Alaa Kamal Jabbar<sup>1</sup>, Mohammed Haethem Qassim<sup>1</sup>, Al-dhahiry Jawad Kadhim Shnayeh (2015) "Clinical evaluation of T3, T4 and TSH thyroid function during first, second and third trimester of pregnancy in Iraqi pregnant women" Vol. 3(3) pp.195-199,
- [165] M. A. Samad<sup>1</sup>, M. M. Haque<sup>1</sup>, M. K. Shah<sup>2</sup>, M. R. Islam<sup>2</sup>, M. C. Mia (2013) "Evaluation of TSH, T4 and T3 in human serum: standardization on normal individuals" *American Journal of Modern Physics* 2(4): 202-207

- [166] DrSudhaJha Dr. Naved Ahmad.(2013) “Prevalence of Thyroid Dysfunction in the Patients Visiting Tertiary Health Care Hospital, Faridabad; Haryana”. International Journal of scientific research (Volume : 2) | 2277pp8174 – 8179.
- [167] Priyatharshini M, Muraliswaran P, Kanagavalli P, Radhika G, and Srikanth (2014) A Retrospective Study of Thyroid Disorders Among Women of Reproductive Age Group in Puducherry Vol5(6) pp748-753
- [168].Primus FJ, Kalley EA *et al.*,(1988) “Sandwich” – Immunoassay of Carcinoembryonic Antigen in patients Receiving Murine Monoclonal Antibodies for diagnosis and therapy. Clin chem.;34:pp261-4.
- [169] Schroff RW, Foon KA *et al.*, (1985)“Human Anti-Murine Immunoglobulin Responses in patients Receiving Monoclonal Antibody therapy”, cancer Res;45:879-85.
- [170]. Boscato LM and Stuart MC. (1988)Heterophilic Antibodies; A problem for All Immunoassay.Clin Chem;pp34:27.